Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Inc.

www.biogen.com

Latest From Biogen Inc.

Biopharma’s Innovation Defense Is Crumbling

The debate over price 'negotiation' in the US has taken a turn for the worse for innovator pharma companies. The Democratic party seems eager to plow forward no matter what the impact is on innovation – and some patient advocates are surprisingly eager to cheer them along.

Pricing Debate Medicare

Patience Needed On US Biosimilars, Says Samsung Bioepis’ Ko

In the first part of an exclusive interview with Generics Bulletin, Samsung Bioepis CEO Christopher Hansung Ko sets out his views on the US biosimilar market.

Strategy Biosimilars

Asia Executives On The Move: Senior Changes At Biogen, Amicus, PhRMA In Japan, Ascletis and Lupin

The coming of autumn ushers in a flurry of executive changes. Biogen has a new R&D head for Japan while Amicus Japan has a  new president, and other executive changes take place at Ascletis, Lupin and industry trade groups PhRMA and IPA.
Appointments Japan

Keeping Track: A Novel Approval For Fluorodopa F 18, A Tentative Approval For Vumerity, And A Missed Goal Date For Zilretta

The latest drug development news and highlights from our US FDA Performance Tracker.

US FDA Performance Tracker Approvals
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register